An Update on Drug-induced Liver Injury

1972, International drug monitoring: the role of national centres. Report of a WHO meeting, WHO Tech Rep Ser, 498, 1 Edwards, 2000, Adverse drug reactions: definition, diagnosis and management, Lancet, 356, 1255, 10.1016/S0140-6736(00)02799-9 Navarro, 2006, Drug-related hepatotoxicity, N Engl J Med, 354, 731, 10.1056/NEJMra052270 Watkins, 2011, Drug safety sciences and the bottleneck in drug development, Clin Pharmacol Ther, 89, 788, 10.1038/clpt.2011.63 Pirmohamed, 2004, Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients, BMJ, 329, 15, 10.1136/bmj.329.7456.15 Meier, 2005, Incidence of drug-induced liver injury in medical inpatients, Eur J Clin Pharmacol, 61, 135, 10.1007/s00228-004-0888-z De Valle, 2006, Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic, Aliment Pharmacol Ther, 24, 1187, 10.1111/j.1365-2036.2006.03117.x Sgro, 2002, Incidence of drug-induced hepatic injuries: a French population-based study, Hepatology, 36, 451, 10.1053/jhep.2002.34857 Devarbhavi, 2010, Single-center experience with drug-induced liver injury from India: causes, outcome, prognosis, and predictors of mortality, Am J Gastroenterol, 105, 2396, 10.1038/ajg.2010.287 Vuppalanchi, 2007, Etiology of new-onset jaundice: how often is it caused by idiosyncratic drug-induced liver injury in the United States?, Am J Gastroenterol, 102, 558, 10.1111/j.1572-0241.2006.01019.x Hussaini, 2007, Antibiotic therapy: a major cause of drug-induced jaundice in southwest England, Eur J Gastroenterol Hepatol, 19, 15, 10.1097/01.meg.0000250581.77865.68 Larson, 2005, Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study, Hepatology, 42, 1364, 10.1002/hep.20948 Reuben, 2010, Drug-induced acute liver failure: results of a U.S. multicenter, prospective study, Hepatology, 52, 2065, 10.1002/hep.23937 Kumar, 2010, Antituberculosis therapy-induced acute liver failure: magnitude, profile, prognosis, and predictors of outcome, Hepatology, 51, 1665, 10.1002/hep.23534 Devarbhavi, 2005, Fulminant hepatic failure: cause, course and predictors of outcome, Ind J Gastroenterol, 24, A116 Devarbhavi, 2011, Drug-Induced liver injury with hypersensitivity features has a better outcome: a single-center experience of 39 children and adolescents, Hepatology, 54, 1344, 10.1002/hep.24527 Devarbhavi, 2010, Antituberculosis therapy drug-induced liver injury and acute liver failure, Hepatology, 52, 798, 10.1002/hep.23805 Andrade, 2005, Spanish group for the study of drug-induced liver disease. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period, Gastroenterology, 129, 512, 10.1016/j.gastro.2005.05.006 Chalasani, 2008, Drug induced liver injury network (DILIN). Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States, Gastroenterology, 135, 1924, 10.1053/j.gastro.2008.09.011 Bjornsson, 2005, Outcome and prognostic markers in sever drug-induced liver disease, Hepatology, 42, 481, 10.1002/hep.20800 Takikawa, 2009, Drug-induced liver injury in Japan: an analysis of 1676 cases between 1997 and 2006, Hepatol Res, 39, 427, 10.1111/j.1872-034X.2008.00486.x Benichou, 1990, Criteria of DILI. Report of an international consensus meeting, J Hepatol, 11, 272 Danan, 1993, Causality assessment of adverse reactions to drugs – I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries, J Clin Epidemiol, 46, 1323, 10.1016/0895-4356(93)90101-6 Fontana, 2010, Standardization of nomenclature and causality in drug-induced liver injury: summary of a clinical research workshop, Hepatology, 52, 730, 10.1002/hep.23696 Saukkonen, 2006, Hepatotoxicity of antituberculosis therapy subcommittee, Am J Respir Crit Care Med, 174, 935, 10.1164/rccm.200510-1666ST Verma, 2009, Diagnosis, management and prevention of drug-induced liver injury, Gut, 58, 1555, 10.1136/gut.2008.163675 Aithal, 2011, Case definition and phenotype standardization in drug-induced liver injury, Clin Pharmacol Ther, 89, 806, 10.1038/clpt.2011.58 Temple, 2006, Hy's law: predicting serious hepatotoxicity, Pharmacoepidemiol Drug Saf, 15, 241, 10.1002/pds.1211 Zimmerman, 1999 Shapiro, 2007, Causality assessment and drug-induced hepatotoxicity: promises and pitfalls, Clin Liver Dis, 11, 477, 10.1016/j.cld.2007.06.003 Senior, 2009, Monitoring for hepatotoxicity: what is the predictive value of liver “function” tests?, Clin Pharmacol Ther, 85, 331, 10.1038/clpt.2008.262 Björnsson, 2009, The long-term follow-up after idiosyncratic drug-induced liver injury with jaundice, J Hepatol, 50, 511, 10.1016/j.jhep.2008.10.021 Naranjo, 1981, A method for estimating the probability of adverse drug reactions, Clin Pharmacol Ther, 30, 239, 10.1038/clpt.1981.154 Maria, 1997, Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis, Hepatology, 26, 664, 10.1002/hep.510260319 Rockey, 2010, Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method, Hepatology, 51, 2117, 10.1002/hep.23577 Sarda, 2009, Role of acute viral hepatitis as a confounding factor in antituberculosis treatment induced hepatotoxicity, Indian J Med Res, 129, 64 Davern, 2011, Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury, Gastroenterology, 141, 1665, 10.1053/j.gastro.2011.07.051 Lucena, 2001, Comparison of two clinical scales for causality assessment in hepatotoxicity, Hepatology, 33, 123, 10.1053/jhep.2001.20645 Tujios, 2011, Mechanisms of drug-induced liver injury: from bedside to bench, Nat Rev Gastroenterol Hepatol, 8, 202, 10.1038/nrgastro.2011.22 Holt, 2006, Mechanisms of drug-induced liver injury, AAPS J, 8, E48, 10.1208/aapsj080106 Abboud, 2007, Drug-induced liver injury, Drug Saf, 30, 277, 10.2165/00002018-200730040-00001 Mehal, 2001, Immunology of the healthy liver: old questions and new insights, Gastroenterology, 120, 250, 10.1053/gast.2001.20947 Bjornsson, 2007, The impact of eosinophilia and hepatic necrosis on prognosis in patients with drug-induced liver injury, Aliment Pharmacol Ther, 25, 1411, 10.1111/j.1365-2036.2007.03330.x Matzinger, 1994, Tolerance, danger, and the extended family, Annu Rev Immunol, 12, 991, 10.1146/annurev.iy.12.040194.005015 Kaplowitz, 2005, Idiosyncratic drug hepatotoxicity, Nat Rev Drug Discov, 4, 489, 10.1038/nrd1750 Shayiq, 1999, Repeat exposure to incremental doses of acetaminophen provides protection against acetaminophen-induced lethality in mice: an explanation for high acetaminophen dosage in humans without hepatic injury, Hepatology, 29, 451, 10.1002/hep.510290241 Deng, 2009, Inflammatory stress and idiosyncratic hepatotoxicity: hints from animal models, Pharmacol Rev, 61, 262, 10.1124/pr.109.001727 Shaw, 2010, Idiosyncratic drug-induced liver injury and the role of inflammatory stress with an emphasis on an animal model of trovafloxacin hepatotoxicity, Toxicol Sci, 118, 7, 10.1093/toxsci/kfq168 Björnsson, 2010, Drug-induced autoimmune hepatitis: clinical characteristics and prognosis, Hepatology, 51, 2040, 10.1002/hep.23588 Suzuki, 2011, The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury, Hepatology, 54, 931, 10.1002/hep.24481 Kakuda, 2000, Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity, Clin Ther, 22, 685, 10.1016/S0149-2918(00)90004-3 Lheureux, 2009, Carnitine in the treatment of valproic acid-induced toxicity, Clin Toxicol (Phila), 47, 101, 10.1080/15563650902752376 Goodman, 2002, Drug hepatotoxicity, Clin Liver Dis, 6, 381, 10.1016/S1089-3261(02)00011-9 Lakehal, 2001, Indirect cytotoxicity of flucloxacillin toward human biliary epithelium, Chem Res Toxicol, 14, 694, 10.1021/tx0002435 Iverson, 2001, Identification of reactive metabolite of terbinafine, Chem Res Toxicol, 14, 175, 10.1021/tx0002029 Kullack-Ublick, 2000 Russman, 2010, Pharmacogenetics of drug-induced liver injury, Hepatology, 52, 748, 10.1002/hep.23720 Zollner, 2010, Nuclear receptors as drug targets in cholestasis and drug-induced hepatotoxicity, Pharmacol Ther, 126, 228, 10.1016/j.pharmthera.2010.03.005 Molleston, 2011, Characteristics of idiosyncratic drug-induced liver injury in children: results from the DILIN prospective study, J Pediatr Gastroenterol Nutr, 53, 182, 10.1097/MPG.0b013e31821d6cfd Gronhagen-Riska, 1978, Predisposing factors in hepatitis induced by isoniazid–rifampin treatment of tuberculosis, Am Rev Resp Dis, 118, 461 Yew, 2002, Clinically significant interactions with drugs used in the treatment of tuberculosis, Drug Saf, 25, 111, 10.2165/00002018-200225020-00005 Wright, 1982, Isoniazid-induced carbamazepine toxicity and vice versa: a double drug interaction, N Engl J Med, 307, 1325, 10.1056/NEJM198211183072107 Yee, 2003, Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis, Am J Respir Crit Care Med, 167, 1472, 10.1164/rccm.200206-626OC Grosset, 1992, Antagonism between isoniazid and the combination pyrazinamide–rifampin against tuberculosis infection in mice, Antimicrob Agents Chemother, 36, 548, 10.1128/AAC.36.3.548 Jasmer, 2002, Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial, Ann Intern Med, 137, 640, 10.7326/0003-4819-137-8-200210150-00007 Singla, 2010, Evaluation of risk factors for antituberculosis treatment induced hepatotoxicity, Indian J Med Res, 132, 81 Sharma, 2002, Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment, Am J Respir Crit Care Med, 166, 916, 10.1164/rccm.2108091 Jain, 2007, Drug-induced liver injury associated with HIV medications, Clin Liver Dis, 11, 615, 10.1016/j.cld.2007.06.008 Núñez, 2006, Hepatotoxicity of antiretrovirals: incidence, mechanisms and management, J Hepatol, 44, S132, 10.1016/j.jhep.2005.11.027 Yimer, 2011, Pharmacogenetic and pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients, PLoS One, 6, e27810, 10.1371/journal.pone.0027810 Mallal, 2008, HLA-B*5701 screening for hypersensitivity to abacavir, N Engl J Med, 358, 568, 10.1056/NEJMoa0706135 Cotte, 2011, The role of nucleoside and nucleotide analogues in nodular regenerative hyperplasia in HIV-infected patients: a case control study, J Hepatol, 54, 489, 10.1016/j.jhep.2010.07.030 Wong, 2000, Antituberculosis drug- related liver dysfunction in chronic hepatitis B, Hepatology, 31, 201, 10.1002/hep.510310129 Sulkowski, 2000, Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection, JAMA, 283, 74, 10.1001/jama.283.1.74 den Brinker, 2000, Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection, AIDS, 14, 2895, 10.1097/00002030-200012220-00011 Hwang, 1997, A prospective clinical study of isoniazid–rifampicin–pyrazinamide-induced liver injury in an area endemic for hepatitis B, J Gastroenterol Hepatol, 12, 87, 10.1111/j.1440-1746.1997.tb00353.x Lee, 2005, Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy, Chest, 127, 1304, 10.1378/chest.127.4.1304 Wang, 2011, Risk factors of hepatitis during anti-tuberculous treatment and implications of hepatitis virus load, J Infect, 62, 448 Huang, 2002, Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis, Hepatology, 35, 883, 10.1053/jhep.2002.32102 Bose, 2011, Role of polymorphic N-acetyl transferase2 and cytochrome P4502E1 gene in antituberculosis treatment-induced hepatitis, J Gastroenterol Hepatol, 26, 312, 10.1111/j.1440-1746.2010.06355.x Roy, 2001, Increased risk of antituberculosis drug-induced hepatotoxicity in individuals with glutathione S-transferase M1 ‘null’ mutation, J Gastroenterol Hepatol, 16, 1033, 10.1046/j.1440-1746.2001.02585.x Vuilleumier, 2006, CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis, Eur J Clin Pharmacol, 62, 423, 10.1007/s00228-006-0111-5 Chatterjee, 2010, GSTT1 and GSTM1 gene deletions are not associated with hepatotoxicity caused by antitubercular drugs, Clin Pharmacol Ther, 35, 465, 10.1111/j.1365-2710.2009.01101.x Hautekeete, 1999, HLA-association of amoxicillin–clavulanate-induced hepatitis, Gastroenterology, 117, 1181, 10.1016/S0016-5085(99)70404-X Andrade, 2004, HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease, Hepatology, 39, 1603, 10.1002/hep.20215 Lucena, 2011, Susceptibility to amoxicillin–clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles, Gastroenterology, 141, 338, 10.1053/j.gastro.2011.04.001 Donaldson, 2010, Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury, J Hepatol, 53, 1049, 10.1016/j.jhep.2010.05.033 Daly, 2009, HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin, Nat Genet, 4, 816, 10.1038/ng.379 Lammert, 2008, Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals, Hepatology, 47, 2003, 10.1002/hep.22272 Lammert, 2010, Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events, Hepatology, 51, 615, 10.1002/hep.23317 Hunt, 2010, Mitochondrial and immunoallergic injury increase risk of positive drug rechallenge after drug-induced liver injury: a systematic review, Hepatology, 52, 2216, 10.1002/hep.24022 Andrade, 2009, Rechallenge in drug-induced liver injury: the attractive hazard, Expert Opin Drug Saf, 8, 709, 10.1517/14740330903397378 Krivoy, 2006, Antiepileptic drug-induced hypersensitivity syndrome reactions, Current Drug Safety, 1, 289, 10.2174/157488606777934459 Sharma, 2010, Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity, Clin Infect Dis, 50, 833, 10.1086/650576 Tahaoðlu, 2001, The management of anti-tuberculosis drug-induced hepatotoxicity, Int J Tuberc Lung Dis, 5, 65 Roenigk, 1998, Methotrexate in psoriasis: consensus conference, J Am Acad Dermatol, 38, 478, 10.1016/S0190-9622(98)70508-0 Aithal, 2004, Monitoring methotrexate-induced hepatic fibrosis in patients with psoriasis: are serial liver biopsies justified?, Aliment Pharmacol Ther, 19, 391, 10.1046/j.1365-2036.2004.01819.x Aithal, 2007, Dangerous liaisons: drug, host and the environment, J Hepatol, 46, 995, 10.1016/j.jhep.2007.03.017 Rosenberg, 2007, Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment, J Hepatol, 46, 1111, 10.1016/j.jhep.2007.01.024 Lee, 2009, Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure, Gastroenterology, 137, 856, 10.1053/j.gastro.2009.06.006 Baniasadi, 2010, Protective effect of N-acetylcysteine on antituberculosis drug-induced hepatotoxicity, Eur J Gastroenterol Hepatol, 22, 1235, 10.1097/MEG.0b013e32833aa11b Enjalbert, 2002, Treatment of amatoxin poisoning: 20-year retrospective analysis, J Toxicol Clin Toxicol, 40, 715, 10.1081/CLT-120014646 Bohan, 2001, Effect of l-carnitine treatment for valproate-induced hepatotoxicity, Neurology, 56, 1405, 10.1212/WNL.56.10.1405 Stapelbroek, 2010, Liver disease associated with canalicular transport defects: current and future therapies, J Hepatol, 52, 258, 10.1016/j.jhep.2009.11.012 Smith, 2005, Vanishing bile duct syndrome: amoxicillin–clavulanic acid associated intra-hepatic cholestasis responsive to ursodeoxycholic acid, J Pediatr Gastroenterol Nutr, 41, 469, 10.1097/01.mpg.0000178086.44155.73 van Roon, 2004, Leflunomide for the treatment of rheumatoid arthritis in clinical practice: incidence and severity of hepatotoxicity, Drug Saf, 27, 345, 10.2165/00002018-200427050-00006 Giannattasio, 2006, Steroid therapy for a case of severe drug-induced cholestasis, Ann Pharmacother, 40, 1196, 10.1345/aph.1G345